Secondary Sales and Founder Liquidity in University Spinouts

A secondary sale is the transfer of already-issued shares from one existing holder — typically a founder, early employee, or early investor — to a new buyer, with no new capital raised by the company itself. It is distinct from a primary financing round (where the company issues new shares for cash that goes onto its own balance sheet) and distinct from an exit (an acquisition, IPO, or wind-down that ends the company’s life as an independent entity). A secondary sale is a change of ownership in existing stock, executed while the company keeps operating and raising primary capital on its own separate timeline.

For university spinout founders — most of whom are academic researchers with the bulk of their net worth tied up in illiquid, unvested or restricted equity for years before any acquisition or IPO — secondary sales are one of the only realistic ways to access any cash from that equity before a full exit. This guide covers how secondary transactions actually work in venture-backed spinouts, the consent and transfer mechanics that make university-affiliated cap tables distinctive, the tax treatment that materially changes the economics for both seller and buyer, and where a founder’s ability to sell is genuinely constrained.

How a secondary sale differs from a primary round or an exit

These three events are often conflated by founders new to venture mechanics, but they involve different parties, different cash flows, and different legal documents:

• Primary financing — the company issues new shares directly to an investor in exchange for cash that goes onto the company’s own balance sheet, funding operations. Existing shareholders are diluted (see CASRAI’s guide on equity dilution across funding rounds) but do not receive any cash themselves.
• Secondary sale — an existing shareholder sells shares they already hold to a buyer (a new investor, an existing investor increasing its position, or, less commonly, the company itself via a buyback). The seller receives cash directly; the company’s balance sheet and share count are unaffected (a straight secondary) or its share count contracts slightly (a company buyback/redemption).
• Exit — an acquisition, IPO, or wind-down that changes the company’s fundamental structure or independent existence. See CASRAI’s guide on spinout exit strategies for that separate topic.

A secondary sale can happen at almost any stage after shares exist and are transferable — commonly alongside a new primary round (an investor negotiates to buy some primary and some secondary shares in the same financing), through an organized company tender offer, or through a private bilateral trade, sometimes brokered via a marketplace platform.

Why founders and early investors want liquidity before an exit

The case for partial liquidity is largely about risk management rather than distrust in the company:

• Concentration risk. A researcher-founder with the overwhelming majority of personal net worth in one illiquid, unvested asset carries far more single-company risk than a diversified investor holding the same nominal stake. Taking some money off the table reduces that concentration without requiring the founder to leave or the company to sell.
• Time-to-exit has lengthened. Companies are staying private longer before an IPO or acquisition than they did a decade ago, which means founder equity that would once have converted to cash in five to seven years may now be illiquid for a decade or more.
• Early-investor fund cycles. A university’s own affiliated seed/evergreen fund, a founder’s earliest angel backers, or an early institutional investor may need to return capital to their own limited partners well before the company itself is ready to exit — a secondary sale of part of their position lets them do that without forcing the company’s hand.
• Retention. For a venture board and existing investors, a modest secondary sale for a key founder can be a retention tool — it relieves enough personal financial pressure that the founder is less likely to leave for a role with faster liquidity, without diluting the company’s own cap table.

None of this is unique to university spinouts, but the university-affiliated cap table adds constraints that a typical venture-backed startup founder does not face — covered below.

The consent mechanics: ROFR, co-sale rights, and company approval

Founder and early-investor shares are almost never freely transferable. Most spinout stock purchase agreements and the company’s own bylaws or investor rights agreement impose several layered restrictions, closely modeled on the NVCA (National Venture Capital Association) model documents used across the venture industry generally:

• Right of first refusal (ROFR). Before a shareholder can sell to an outside buyer, the company itself typically has the first right to buy the shares on the same terms; if the company passes, that right often flows through to the company’s major preferred investors, usually pro rata to their existing holdings. A seller cannot simply find a buyer and close — the proposed sale has to be offered to the company (and often the investor base) first, on a defined notice period.
• Co-sale (tag-along) rights. Major investors frequently have the right to sell a proportional slice of their own shares alongside a founder’s proposed secondary sale, so a founder cannot cash out disproportionately to the company’s largest backers without giving them the same opportunity.
• Board or company consent. Beyond ROFR, many spinout charters require the board — or in some cases the university itself, where it holds a board seat or a contractual consent right tied to its own equity stake or licensing agreement — to approve any transfer of founder shares, particularly while vesting is still in progress.
• Waiver in practice. Companies frequently choose to waive their ROFR and let an organized secondary transaction proceed rather than use company cash to buy shares back, especially in a company-sponsored tender offer where the point is explicitly to give employees and founders liquidity. Whether ROFR gets exercised or waived is a real board-level decision, not a formality — treat it as a live negotiation point, not an assumption.

For a university spinout specifically, add one more layer: the university’s own equity stake (commonly negotiated as part of the license agreement that spun the technology out in the first place) and any related contractual restrictions on the founder’s own shares while they remain a university employee or PI on sponsored research tied to the underlying IP. A founder should confirm with the technology transfer office (TTO) and university counsel whether the university’s license agreement or any related conflict-of-interest management plan imposes its own transfer restrictions or consent requirements on founder equity — these sit alongside, not instead of, the standard investor-side ROFR/co-sale mechanics above.

How a secondary sale is actually structured

• Direct/bilateral secondary. A single buyer (often an existing investor increasing its position, or a new investor gaining access to a company it couldn’t otherwise get into) negotiates directly with an individual seller. Simplest structure, but still subject to the consent mechanics above.
• Structured alongside a primary round. An investor leading a new financing round negotiates to buy a portion of newly issued primary shares and a portion of secondary shares from founders/early holders in the same transaction — common when a lead investor wants a larger position than the round size alone would allow, and the company wants to give a founder or early backer some liquidity without depleting the company’s own cash.
• Company-organized tender offer. The company (or a company-invited investor) makes a structured offer to buy back a defined dollar amount or percentage of shares from a defined pool of eligible sellers (often current and former employees, sometimes including founders), on a common price and a fixed window. This spreads liquidity across more people than a one-off bilateral trade and is more common at growth-stage private companies than at early-stage spinouts.
• Secondary marketplace platforms. Platforms exist that broker secondary transactions in private company stock, though access and liquidity vary widely by company and are less commonly used for early-stage, narrowly-held spinout cap tables than for later-stage, broadly-optioned private companies.

Across structures, secondary pricing commonly sits below the company’s most recent primary-round valuation — buyers of secondary shares are typically acquiring common stock (with fewer contractual rights and protections than the preferred stock primary investors hold) and are compensated for that, and for illiquidity risk, with a discount to the last preferred price. The size of that discount varies by company, structure, and market conditions, and should not be assumed to be a fixed figure — it is a genuinely negotiated term in every transaction.

Tax treatment: why QSBS status matters, and why it doesn’t automatically transfer

Under IRC Section 1202 (Qualified Small Business Stock, “QSBS”), a founder or early investor who acquired their stock directly from a qualifying C-corporation at original issuance — not by purchasing it from another existing shareholder — and holds it for the required period can potentially exclude a substantial portion of their capital gain from federal tax on a later sale. See CASRAI’s comparison of Delaware C-corp vs. LLC for university spinouts for why entity choice matters to QSBS eligibility in the first place.

Two distinct points matter for a secondary sale specifically, and they are easy to conflate:

• The seller’s own gain. A founder selling QSBS-eligible shares they originally received directly from the company (e.g., founder stock issued at incorporation) in a secondary transaction is generally still selling their own originally-issued stock — the secondary sale is simply how they’re disposing of it. Whether the seller’s gain qualifies for the Section 1202 exclusion depends on whether their own acquisition and holding-period facts independently satisfy the statute, not on the fact that the transaction happens to be structured as a ‘secondary’ sale.
• The buyer’s QSBS status going forward. A buyer who purchases shares from an existing shareholder in a secondary transaction — rather than acquiring newly issued stock directly from the company — generally does not get the benefit of QSBS treatment on that stock, because they did not meet the original-issuance requirement themselves. This is one of the reasons secondary buyers price in a discount: the shares they’re acquiring may carry less favorable future tax treatment for them than a primary investment in the same company would.

QSBS rules have limited statutory exceptions (transfers by gift, at death, or in certain partnership distributions can preserve QSBS treatment for the recipient) and the holding-period and exclusion-cap rules themselves are detailed and have been subject to legislative change. This is genuinely fact-specific, jurisdiction- and transaction-dependent tax law — a founder or early investor contemplating a secondary sale should get advice from a tax attorney or CPA experienced in QSBS before assuming any particular tax outcome, not rely on general guidance like this page.

Constraints specific to unvested or restricted founder equity

Most founder stock in a venture-backed spinout is subject to vesting (see CASRAI’s guide on founder equity vesting schedules), and unvested shares are essentially never eligible for a secondary sale — a buyer has no interest in purchasing stock the company can repurchase at a nominal price if the founder departs before it vests, and most stock purchase agreements do not even permit the transfer of unvested shares. In practice, this means founders typically cannot access secondary liquidity on any meaningful scale until a substantial portion of their vesting schedule has completed, which for a standard four-year schedule with a one-year cliff can mean a multi-year wait even after the company itself becomes an attractive secondary-market target.

Founders should also check their stock purchase agreement and any separate lock-up or standstill provisions negotiated in a later financing round — some rounds include founder lock-up commitments (a period during which founders agree not to sell any shares) as a condition of new investors participating, independent of the standard ROFR/co-sale mechanics described above.

A practical checklist before pursuing a secondary sale

1. Confirm what percentage of your shares is actually vested and unrestricted as of today — only that portion is realistically saleable.
2. Read your stock purchase agreement and the company’s investor rights/right-of-first-refusal agreement to identify the exact consent chain (company ROFR, investor co-sale, board approval) and notice periods involved.
3. Check with the TTO and university counsel whether the university’s license agreement, conflict-of-interest management plan, or any other university-side agreement imposes its own restriction or consent requirement on your equity.
4. Talk to the company (typically the CEO or CFO, and often the board) before shopping shares — an unsanctioned attempt to sell without going through ROFR is a breach of contract, not just a bad look, and most successful founder secondaries happen with company knowledge and cooperation, often structured alongside a financing round or tender offer the company itself organizes.
5. Get independent tax advice on your specific QSBS facts (acquisition date, holding period, entity structure) before assuming any exclusion applies to your sale.
6. Understand the pricing discount you should reasonably expect relative to the last primary round, and don’t treat the last round’s preferred price as your reference point for what a secondary buyer will pay for common stock.

Frequently asked questions

Can a university spinout founder sell shares before the company is acquired or goes public?

Sometimes, but only the vested, unrestricted portion of their holding, and only through the consent process set out in the company’s own governing documents (ROFR, co-sale rights, and often board or investor approval) — a founder cannot unilaterally sell private company stock the way they could sell public stock.

Does a secondary sale dilute other shareholders?

No, in the ordinary case — a straight secondary sale simply transfers existing shares from one holder to another; it does not change the total share count or the company’s own capital, unlike a primary financing round, which does dilute existing holders by issuing new shares.

Is a secondary sale the same as an acquihire or an exit?

No. A secondary sale is a change of ownership in existing shares while the company continues operating independently; an acquisition, acquihire, or IPO ends the company’s separate private existence. See CASRAI’s guide on spinout exit strategies for that distinct topic.

Do secondary buyers get the same QSBS tax benefits as original investors?

Generally not on the shares they acquire in the secondary purchase itself, because Section 1202 requires original issuance directly from the company — buying from an existing shareholder does not meet that requirement for the buyer. This is a genuinely fact-specific area of tax law; get professional advice before relying on any particular outcome.

Who has to approve a founder’s secondary sale?

Typically the company first (via a right of first refusal), then often the company’s major investors (via co-sale rights if the company passes), and depending on the company’s governing documents, the board. University-affiliated founders should separately confirm whether the university itself has any consent right tied to its own equity stake or license agreement.

For the broader mechanics of how spinout equity is structured and later diluted, see CASRAI’s guides on university spinout equity splits and equity dilution across funding rounds, and the technology transfer pillar page for the full cluster of related commercialization topics.